Charles France, Ph.D.
Robert A. Welch Distinguished University Chair in Chemistry, Professor of Pharmacology, and Professor of Psychiatry
Personal Statement:
Research in the France laboratory focuses on interactions between behavior and pharmacology and how those interactions impact the abuse liability of drugs. One major goal is to understand how the subjective and other abuse-related effects of drugs change as a consequence of particular behavioral and pharmacologic histories. Behavioral procedures developed in this laboratory permit systemic investigation of drug dependence and withdrawal and ongoing studies examine how these phenomena can be modified by behavioral and pharmacologic interventions. A unifying theme of research in the France laboratory is the application of receptor theory to the planning, execution, and interpretation of behavioral pharmacological studies. Thus, many of our studies examine differences in efficacy and selectivity among potential drugs of abuse and potential treatment compounds, thereby identifying the pharmacologic characteristics of drugs that are most important for specific behavioral effects (e.g., reinforcing effects). Current areas of research include the following: the role of different monoamine systems in modifying the abuse and therapeutic effects of opioids; the impact of different diets on the abuse and therapeutic effects of drug acting on serotonin or dopamine systems; interactions between GHB and other “club drugs”; the role of insulin receptor pathways in regulating dopamine transporter activity and sensitivity to stimulants; GABA receptor heterogeneity and the dependence liability of sedative/hypnotics; and the influence of physical dependence on the reinforcing effects of opioids.
Education
Ph.D., University of Michigan
Research
• drug abuse | • opioids |
• benzodiazepines | • neuropharmacology |
• drug discrimination | • self administration |
• dependence | • withdrawal |
RESEARCH GRANTS
Postdoctoral Training in Drug Abuse Research: Behavior & Neurobiology
Behavior, Biology, and Chemistry: Translational Research in Addiction
A novel opioid receptor antagonist for treating abuse and overdose
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
Awards & Accomplishments
President (Elect, 2019-2020; Current, 2020-2021) – American Society for Pharmacology and Experimental Therapeutics (ASPET) Director, Addiction Research, Treatment and Training Center of Excellence (ARTT)
Affiliations
American Society for Pharmacology and Experimental Therapeutics Addiction Research, Treatment and Training Center of Excellence American College of Neuropsychopharmacology American Society for Pharmacology and Experimental Therapeutics American Psychological Association Behavioral Pharmacology Society College on Problems of Drug Dependence Society for Neuroscience Society for Stimulus Properties of Drugs Texas Research Society on Alcoholism
Lab Members
![]() | ![]() |
Lawrence M. Carey, Ph.D., Postdoctoral Fellow | Cindal C. Dominguez, Med, MBA, Manager, Research Operations |
Julia Taylor, Laboratory Supervisor | |
Jacob Tovar, Research Assistant | |
Publications
Countermeasures for Preventing and Treating Opioid Overdose.
Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors.
Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.
Effects of remifentanil/histamine mixtures in rats responding under a choice procedure.
Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.
Effects of opioid/cannabinoid mixtures on impulsivity and memory in rhesus monkeys.
Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.
OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.
Punishment and reinforcement by opioid receptor agonists in a choice procedure in rats.
Effects of daily methocinnamox treatment on fentanyl self-administration in rhesus monkeys.